We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on RGNX. REGENXBIO Inc.'s share was trading at $13.76 as of January 15th.
[caption id="attachment_575379" align="aligncenter" width="750"]REGENXBIO is a clinical-stage biotechnology company focused on the development of gene therapies built on its proprietary NAV Technology platform, leveraging AAV8 and AAV9 vectors. Its lead program, surabgene lomparvovec (sura-vec, ABBV-RGX-314), partnered with...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.